[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Download PDF
Table 1. 
Age and Age-Standardized Characteristics by Current BMI, Nurses' Health Study II, 1989-2003
Age and Age-Standardized Characteristics by Current BMI, Nurses' Health Study II, 1989-2003
Table 2. 
Current BMI and the Incidence of Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
Current BMI and the Incidence of Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
Table 3. 
BMI at Age 18 Years and the Incidence of Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
BMI at Age 18 Years and the Incidence of Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
Table 4. 
Current BMI and the Incidence of Receptor-Specific Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
Current BMI and the Incidence of Receptor-Specific Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
Table 5. 
BMI at Age 18 Years and the Incidence of Receptor-Specific Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
BMI at Age 18 Years and the Incidence of Receptor-Specific Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003
Table 6. 
BMI and the Incidence of Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003, Stratified by Cycle Length (Ages 18-22 Years), Oral Contraceptive Use, and Age
BMI and the Incidence of Breast Cancer in Premenopausal Participants in the Nurses' Health Study II, 1989-2003, Stratified by Cycle Length (Ages 18-22 Years), Oral Contraceptive Use, and Age
1.
Brinton  LASwanson  CA Height and weight at various ages and risk of breast cancer. Ann Epidemiol 1992;2597- 609
PubMedArticle
2.
Harris  RENamboodiri  KKWynder  EL Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992;841575- 1582
PubMedArticle
3.
Vatten  LJKvinnsland  S Prospective study of height, body mass index and risk of breast cancer. Acta Oncol 1992;31195- 200
PubMedArticle
4.
Bruning  PFBonfrer  JMHart  AA  et al.  Body measurements, estrogen availability and the risk of human breast cancer: a case-control study. Int J Cancer 1992;5114- 19
PubMedArticle
5.
Petrek  JAPeters  MCirrincione  CRhodes  DBajorunas  D Is body fat topography a risk factor for breast cancer? Ann Intern Med 1993;118356- 362
PubMedArticle
6.
Tornberg  SACarstensen  JM Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer 1994;69358- 361
PubMedArticle
7.
Taioli  EBarone  JWynder  EL A case-control study on breast cancer and body mass. Eur J Cancer 1995;31A723- 728
PubMedArticle
8.
Franceschi  SFavero  ALa Vecchia  C  et al.  Body size indices and breast cancer risk before and after menopause. Int J Cancer 1996;67181- 186
PubMedArticle
9.
Hu  YHNagata  CShimizu  HKaneda  NKashiki  Y Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan. Breast Cancer Res Treat 1997;4365- 72
PubMedArticle
10.
Tavani  AGallus  SLa Vecchia  C  et al.  Risk factors for breast cancer in women under 40 years. Eur J Cancer 1999;351361- 1367
PubMedArticle
11.
Peacock  SLWhite  EDaling  JRVoigt  LFMalone  KE Relation between obesity and breast cancer in young women. Am J Epidemiol 1999;149339- 346
PubMedArticle
12.
Hall  IJNewman  BMillikan  RCMoorman  PG Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 2000;151754- 764
PubMedArticle
13.
van den Brandt  PASpiegelman  DYaun  SS  et al.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152514- 527
PubMedArticle
14.
de Vasconcelos  ABAzevedo e Silva Mendonca  GSichieri  R Height, weight, weight change and risk of breast cancer in Rio de Janeiro, Brazil. Sao Paulo Med J 2001;11962- 66
PubMedArticle
15.
Friedenreich  CM Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001;1015- 32
PubMedArticle
16.
Cox  DR Regression models and life tables (with discussion). J R Stat Soc Ser B 1972;34187- 220
17.
Marshall  RJChisholm  EM Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med 1985;4337- 344
PubMedArticle
18.
Huang  ZHankinson  SEColditz  GA  et al.  Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;2781407- 1411
PubMedArticle
19.
Coates  RJUhler  RJHall  HI  et al.  Risk of breast cancer in young women in relation to body size and weight gain in adolescence and early adulthood. Br J Cancer 1999;81167- 174
PubMedArticle
20.
Folsom  ARKaye  SAPrineas  RJPotter  JDGapstur  SMWallace  RB Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 1990;131794- 803
PubMed
21.
Lund  EAdami  HOBergstrom  RMeirik  O Anthropometric measures and breast cancer in young women. Cancer Causes Control 1990;1169- 172
PubMedArticle
22.
Mayberry  RM Age-specific patterns of association between breast cancer and risk factors in black women, ages 20 to 39 and 40 to 54. Ann Epidemiol 1994;4205- 213
PubMedArticle
23.
Ursin  GPaganini-Hill  ASiemiatycki  JThompson  WDHaile  RW Early adult body weight, body mass index, and premenopausal bilateral breast cancer: data from a case-control study. Breast Cancer Res Treat 1995;3375- 82
PubMedArticle
24.
Hirose  KTajima  KHamajima  N  et al.  Association of family history and other risk factors with breast cancer risk among Japanese premenopausal and postmenopausal women. Cancer Causes Control 2001;12349- 358
PubMedArticle
25.
Shu  XOJin  FDai  Q  et al.  Association of body size and fat distribution with risk of breast cancer among Chinese women. Int J Cancer 2001;94449- 455
PubMedArticle
26.
Wenten  MGilliland  FDBaumgartner  KSamet  JM Associations of weight, weight change, and body mass with breast cancer risk in Hispanic and non-Hispanic white women. Ann Epidemiol 2002;12435- 444
PubMedArticle
27.
McNee  RKMason  BHNeave  LMKay  RG Influence of height, weight, and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat 1987;9145- 150
PubMedArticle
28.
Schatzkin  APalmer  JRRosenberg  L  et al.  Risk factors for breast cancer in black women. J Natl Cancer Inst 1987;78213- 217
PubMed
29.
Parazzini  Fla Vecchia  CNegri  EBruzzi  PPalli  DBoyle  P Anthropometric variables and risk of breast cancer. Int J Cancer 1990;45397- 402
PubMedArticle
30.
Mannisto  SPietinen  PPyy  MPalmgren  JEskelinen  MUusitupa  M Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer 1996;688- 13
PubMedArticle
31.
Chie  WCLi  CYHuang  CSChang  KJLin  RS Body size as a factor in different ages and breast cancer risk in Taiwan. Anticancer Res 1998;18565- 570
PubMed
32.
Galanis  DJKolonel  LNLee  JLe Marchand  L Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control 1998;9217- 224
PubMedArticle
33.
Kaaks  RVan Noord  PADen Tonkelaar  IPeeters  PHRiboli  EGrobbee  DE Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch “DOM” cohort. Int J Cancer 1998;76647- 651
PubMedArticle
34.
Tung  HTTsukuma  HTanaka  H  et al.  Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn J Clin Oncol 1999;29137- 146
PubMedArticle
35.
Enger  SMRoss  RKPaganini-Hill  ACarpenter  CLBernstein  L Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev 2000;9681- 687
PubMed
36.
Adebamowo  CAOgundiran  TOAdenipekun  AA  et al.  Waist-hip ratio and breast cancer risk in urbanized Nigerian women. Breast Cancer Res 2003;5R18- R24
PubMedArticle
37.
Adebamowo  CAOgundiran  TOAdenipekun  AA  et al.  Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol 2003;13455- 461
PubMedArticle
38.
Lahmann  PHHoffmann  KAllen  N  et al.  Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004;111762- 771
PubMedArticle
39.
Chu  SYLee  NCWingo  PASenie  RTGreenberg  RSPeterson  HB The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study. J Clin Epidemiol 1991;441197- 1206
PubMedArticle
40.
Chang  SBuzdar  AUHursting  SD Inflammatory breast cancer and body mass index. J Clin Oncol 1998;163731- 3735
PubMed
41.
Key  TJPike  MC The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;2429- 43
PubMedArticle
42.
Terry  KLWillett  WCRich-Edwards  JWMichels  KB A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med In press
43.
Terry  KLWillett  WCRich-Edwards  JWHunter  DJMichels  KB Menstrual cycle characteristics and incidence of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005;141509- 1513
PubMedArticle
44.
Baer  HJColditz  GARosner  BA  et al.  Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women. Breast Cancer Res 2005;7R314- R325
PubMedArticle
45.
Michels  KBXue  F Role of birthweight in the etiology of breast cancer. Int J Cancer 2006;1192007- 2025
PubMedArticle
46.
Michels  KBWillett  WC Breast cancer: early life matters. N Engl J Med 2004;3511679- 1681
PubMedArticle
47.
Rosenberg  CRPasternack  BSShore  REKoenig  KLToniolo  PG Premenopausal estradiol levels and risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994;140518- 525
PubMed
48.
Thomas  HVKey  TJAllen  DS  et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997;751075- 1079
PubMedArticle
49.
Kabuto  MAkiba  SStevens  RGNeriishi  KLand  CE A prospective study of estradiol and breast cancer among Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9575- 579
PubMed
50.
Eliassen  AHMissmer  SATworoger  SS  et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;981406- 1415Article
51.
Wysowski  DKComstock  GWHelsing  KJLau  HL Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125791- 799
PubMed
52.
Helzlsouer  KJAlberg  AJBush  TLLongcope  CGordon  GBComstock  GW A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;1879- 85
PubMed
53.
Kaaks  RBerrino  FKey  T  et al.  Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97755- 765
PubMedArticle
54.
Grenman  SRonnemaa  TIrjala  KKaihola  HLGronroos  M Sex steroid, gonadotropin, cortisol, and prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight reduction. J Clin Endocrinol Metab 1986;631257- 1261
PubMedArticle
55.
Potischman  NSwanson  CASiiteri  PHoover  RN Reversal of relation between body mass and endogenous concentrations with menopausal status. J Natl Cancer Inst 1996;88756- 758
PubMedArticle
56.
Randolph  JFSowers  MGold  EB  et al.  Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;881516- 1522
PubMedArticle
57.
Verkasalo  PKThomas  HVAppleby  PNDavey  GKKey  TJ Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women. Cancer Causes Control 2001;1247- 59
PubMedArticle
58.
Zumoff  B Relationship of obesity to blood estrogens. Cancer Res 1982;42 ((8 suppl)) 3289s- 3294s
PubMed
59.
Trichopoulos  DPolychronopoulou  ABrown  JMacMahon  B Obesity, serum cholesterol, and estrogens in premenopausal women. Oncology 1983;40227- 231
PubMedArticle
60.
Haffner  SMKatz  MSStern  MPDunn  JF Relationship of sex hormone binding globulin to overall adiposity and body fat distribution in a biethnic population. Int J Obes 1989;131- 9
PubMed
61.
Dorgan  JFReichman  MEJudd  JT  et al.  The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States). Cancer Causes Control 1995;63- 8
PubMedArticle
62.
De Pergola  GZamboni  MSciaraffia  M  et al.  Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women. Int J Obes Relat Metab Disord 1996;201105- 1110
PubMed
63.
Westhoff  CGentile  GLee  JZacur  HHelbig  D Predictors of ovarian steroid secretion in reproductive-age women. Am J Epidemiol 1996;144381- 388
PubMedArticle
64.
Nagata  CKaneda  NKabuto  MShimizu  H Factors associated with serum levels of estradiol and sex hormone-binding globulin among premenopausal Japanese women. Environ Health Perspect 1997;105994- 997
PubMedArticle
65.
Thomas  HVKey  TJAllen  DS  et al.  Re: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status [letter]. J Natl Cancer Inst 1997;89396- 397
PubMedArticle
66.
Ivandic  APrpic-Krizevac  ISucic  MJuric  M Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity. Metabolism 1998;4713- 19
PubMedArticle
67.
Kraemer  RRSynovitz  LBGimpel  TKraemer  GRJohnson  LGCastracane  VD Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. Metabolism 2001;50488- 493
PubMedArticle
68.
Allen  NEAppleby  PNKaaks  RRinaldi  SDavey  GKKey  TJ Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 2003;1465- 74
PubMedArticle
69.
Kok  PRoelfsema  FFrolich  MMeinders  AEPijl  H Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004;894445- 4449
PubMedArticle
70.
Tufano  AMarzo  PEnrini  RMorricone  LCaviezel  FAmbrosi  B Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause. J Endocrinol Invest 2004;27648- 653
PubMedArticle
71.
Lukanova  ALundin  EZeleniuch-Jacquotte  A  et al.  Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004;150161- 171
PubMedArticle
72.
Bezemer  IDRinaldi  SDossus  L  et al.  C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005;16561- 572
PubMedArticle
73.
Kopelman  PGPilkington  TRWhite  NJeffcoate  SL Abnormal sex steroid secretion and binding in massively obese women. Clin Endocrinol (Oxf) 1980;12363- 369
PubMedArticle
74.
Pasquali  RAntenucci  DMelchionda  N  et al.  Sex hormones in obese premenopausal women and their relationships to body fat mass and distribution, B cell function and diet composition. J Endocrinol Invest 1987;10345- 350
PubMedArticle
75.
Tworoger  SSEliassen  AHMissmer  SA  et al.  Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women. Cancer Epidemiol Biomarker Prev In press
76.
Yen  SJaffe  RBarbieri  R Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management.  Philadelphia, Pa WB Saunders Co1999;
77.
Wee  CCMcCarthy  EPDavis  RBPhillips  RS Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 2000;132697- 704
PubMedArticle
78.
Wee  CCMcCarthy  EPDavis  RBPhillips  RS Obesity and breast cancer screening. J Gen Intern Med 2004;19324- 331
PubMedArticle
79.
Amy  NKAalborg  ALyons  PKeranen  L Barriers to routine gynecological cancer screening for white and African-American obese women. Int J Obes 2006;30147- 155Article
Original Investigation
November 27, 2006

Longitudinal Study on the Role of Body Size in Premenopausal Breast Cancer

Author Affiliations

Author Affiliations: Department of Obstetrics and Gynecology, Obstetrics and Gynecology Epidemiology Center (Drs Michels and Terry), and Department of Medicine, Channing Laboratory (Drs Michels, Terry, and Willett), Brigham and Women's Hospital, Harvard Medical School; and Departments of Epidemiology (Drs Michels and Willett) and Nutrition (Dr Willett), Harvard School of Public Health; Boston, Mass.

Arch Intern Med. 2006;166(21):2395-2402. doi:10.1001/archinte.166.21.2395
Abstract

Background  A high body mass index (BMI) has been related to a reduced risk of breast cancer in premenopausal women. The mechanisms underlying this association have not been elucidated.

Methods  We explored whether factors affecting ovulation may explain the inverse association between BMI (calculated as weight in kilograms divided by the square of height in meters) and breast cancer in 113 130 premenopausal participants in the Nurses' Health Study II. During 1 225 520 person-years of prospective follow-up between 1989 and 2003, 1398 incident cases of invasive breast cancer were diagnosed. Weight, height, ovulatory infertility, menstrual cycle patterns, and a multitude of covariates were assessed throughout follow-up. Cox proportional hazards regression was used to compute hazard ratios and 95% confidence intervals (CIs).

Results  We observed a significant linear inverse trend between current BMI and breast cancer incidence (P<.001) that was not explained by menstrual cycle characteristics or infertility due to an ovulatory disorder (covariate-adjusted hazard ratio for breast cancer in women with a BMI ≥30 vs 20.0-22.4, 0.81; 95% CI, 0.68-0.96). We found BMI at age 18 years to be the strongest predictor of breast cancer incidence (covariate-adjusted hazard ratio for breast cancer in women with a BMI at age 18 years ≥27.5 vs 20.0-22.4, 0.57; 95% CI, 0.41-0.81).

Conclusions  Body size during the early phases of adult life seems to be particularly important in the development of premenopausal breast cancer. Factors other than anovulation are likely to mediate the protection conferred by a high BMI.

The inverse association between body mass index (BMI) and the risk of breast cancer among premenopausal women has been observed in numerous studies,115 but the biological mechanisms underlying this perplexing link have remained largely unresolved. A high BMI can be associated with irregular or long menstrual cycles or with polycystic ovary syndrome (PCOS), and it has been suggested that anovulation, which is associated with such characteristics and with decreased estradiol and progesterone levels, may explain the lower risk of breast cancer in these women. However, few studies have explored whether these or other factors provide mechanistic insights into the unexpected protection that a high body mass confers on the premenopausal breast.

We investigated whether menstrual cycle characteristics, infertility due to an ovulatory disorder, or PCOS might explain the inverse association between BMI and premenopausal breast cancer incidence in participants in the Nurses' Health Study II (NHS II).

METHODS
STUDY POPULATION: NHS II

In 1989, 116 609 female registered nurses aged 25 to 42 years living in 1 of 14 US states responded to a self-administered questionnaire about their medical history and lifestyle. Participants have since been followed up by means of biennial questionnaires updating information on demographic variables, lifestyle factors, and medical events.

For this analysis, women were excluded at baseline in 1989 if they were postmenopausal (n = 2813), reported cancer (n = 989), were missing the date of diagnosis of invasive breast cancer (n = 28), or were missing information on height or weight (n = 322) (not mutually exclusive). This study was approved by the institutional review boards of Brigham and Women's Hospital and Harvard School of Public Health.

ASSESSMENT OF EXPOSURE AND COVARIATE INFORMATION

Information on height, weight at age 18 years, and current weight was obtained via the NHS II baseline questionnaire in 1989. The information on current weight was updated every 2 years. The BMI was calculated (as weight in kilograms divided by the square of height in meters) for age 18 years and at all prospective follow-up questionnaire cycles.

On the baseline questionnaire, participants reported characteristics of their menstrual cycle. Information was requested on cycle length (<21 days, 21-25 days, 26-31 days, 32-39 days, 40-50 days, >50 days, or too irregular to estimate) and pattern (very regular [±3 days], regular, usually irregular, always irregular, or no periods) at ages 18 to 22 years, “excluding time around pregnancies or when using oral contraceptives.” In 1993, the participants were asked to describe their current menstrual cycle length and pattern using the same categories offered in the baseline questionnaire.

Infertility status was assessed at baseline and on every subsequent questionnaire. Participants were asked whether they had tried to get pregnant for 1 year without success. If they answered “yes,” they were asked to indicate the cause(s) of their infertility: tubal blockage, ovulatory disorder, endometriosis, cervical mucous factors, factors related to their spouse, no investigation done, cause not found, or other. Polycystic ovary syndrome was defined as probable if a participant had at least 3 of the following 4 characteristics: hirsutism, a BMI of 27 or greater, irregular menstrual cycles, and infertility due to an ovulatory disorder.

Information on potential confounding variables was assessed at baseline and during follow-up. Participants were asked for their date of birth, age at menarche, and family history of breast cancer (in mother, sister, or grandmother) at baseline. History of benign breast disease, parity, age at first birth, alcohol consumption, oral contraceptive use, and physical activity were assessed via the baseline and subsequent questionnaires. Data from subsequent questionnaires were used to update information on confounding variables for each individual in each period.

ASCERTAINMENT OF BREAST CANCER CASES

New cases of breast cancer were identified through the biennial questionnaires mailed between 1989 and 2003. Deaths were reported by family members or by the US Postal Service in response to the follow-up questionnaires, and the National Death Index was searched to investigate the deaths of nonresponders. When a case of breast cancer was reported, we asked the participant (or next of kin for those who had died) for confirmation of the diagnosis and for permission to obtain relevant hospital records and pathology reports. Medical records were obtained for more than 90% of the cases. Pathology reports confirmed breast cancer in more than 99% of the women whose reports were reviewed. We restricted the study end point to invasive breast cancer. Cases of carcinoma in situ were censored at the time of diagnosis.

STATISTICAL ANALYSIS

Women were followed up prospectively from the time they first reported their weight and height in 1989 until the end of follow-up in 2003. Person-years of follow-up were calculated as the time from completion of the 1989 questionnaire to the date of return of the 2003 questionnaire, the date of diagnosis of invasive or in situ breast cancer, any other cancer (except nonmelanoma skin cancer), death, loss to follow-up, or reaching menopause, whichever occurred first. Women were also censored if they did not report their weight on 3 or more questionnaires. The total number of observations varied between analyses depending on the number of women missing the main exposure (ie, current BMI or BMI at age 18 years) or outcome of interest (ie, receptor-specific breast cancer).

A Cox proportional hazards regression model16 was used to calculate the hazard of developing invasive breast cancer associated with a particular level of BMI. For the analysis of current BMI, weight reported on the questionnaire preceding the report of an incident breast cancer diagnosis was used. We assessed the association between current BMI or BMI at age 18 years and breast cancer incidence, adjusting for age (in months), family history of breast cancer in a first-degree relative (dichotomous), history of benign breast disease (dichotomous), age at menarche (≤10, 11, 12, 13, 14, or ≥15 years), parity (0, 1, 2, 3, or ≥4), age at first birth (≤24, 25-30, or >30 years), oral contraceptive use (never, past for <5 years, past for ≥5 years, current for <5 years, current for 5-9 years, or current for ≥10 years), alcohol intake (none, <7.5 g/d, 7.5-14 g/d, >15-29 g/d, or ≥30 g/d), physical activity (<3, 3-8, 9-17, 18-26, 27-41, or ≥42 metabolic equivalents per week), menstrual cycle characteristics (≤25 days and regular, 26-31 days and regular, ≥32 days and regular, ≤25 days and irregular, 26-31 days and irregular, or ≥32 days and irregular), infertility due to an ovulatory disorder (dichotomous), and probable PCOS (dichotomous). Covariate values were updated in the analysis whenever new information was obtained from the biennial questionnaire.

Analyses were stratified by menstrual cycle length (<32 vs ≥32 days), age (<40 vs ≥40 years), and use of oral contraceptives (current, past, or never). Effect modification was assessed by creating the cross-products between BMI and each potential effect modifier. We measured the significance of potential effect modification using the likelihood ratio test, comparing a model with the cross-products representing interaction terms and the nested model without these terms. Separate analyses were performed for estrogen receptor (ER)-positive and ER-negative breast cancer and for progesterone receptor (PR)-positive and PR-negative breast cancer. We used polychotomous logistic regression with 3 outcome categories (ER-positive breast cancer, ER-negative breast cancer, and no breast cancer or PR-positive breast cancer, PR-negative breast cancer, and no breast cancer) to evaluate whether trends in BMI at age 18 years and in current BMI differed by the receptor status of the tumor. Likelihood ratio tests with 1 df were used to compare a model with different slopes for each outcome with a model with a common slope. We used χ2 tests to obtain 2-sided P values for the likelihood ratio statistics.17 Trend tests were performed using the midpoint of the intervals. All the tests of statistical significance were 2-sided.

RESULTS

During 1 225 520 person-years of follow-up, 1398 incident cases of invasive breast cancer were diagnosed in this premenopausal population, which included 113 130 women. Women with a higher current BMI were older, had a higher BMI at age 18 years, had an earlier age at menarche, were less likely to have a history of benign breast disease, were more likely to report menstrual cycle irregularity in 1993 and a history of ovulatory infertility, and reported lower alcohol consumption than women with a lower BMI (Table 1). Women on both ends of the BMI distribution were more likely to be nulliparous than women in the middle categories (Table 1).

We observed a significant linear inverse trend between current BMI and breast cancer incidence (P<.001) (Table 2). Women with a BMI of 30.0 or higher had an age-adjusted hazard ratio for breast cancer of 0.79 (95% confidence interval [CI], 0.67-0.94) compared with women with a BMI between 20.0 and 22.4. Further adjustment for a family history of breast cancer, a history of benign breast disease, height, age at menarche, age at first birth, parity, alcohol consumption, physical activity, and current or past use of oral contraceptives did not alter this estimate appreciably (Table 2). Additionally, adjusting for menstrual cycle characteristics, infertility due to an ovulatory disorder, or probable PCOS similarly did not affect the estimates (Table 2). When the analysis of current BMI and breast cancer was adjusted for BMI at age 18 years, the association was considerably attenuated, eliminating the previously significant trend (Table 2). Restricting the analysis to women with no reported history of infertility due to an ovulatory disorder did not appreciably change the results (data not shown). Body mass index at age 18 years was significantly inversely associated with the incidence of premenopausal breast cancer (Table 3). Women with a BMI of 27.5 or higher at age 18 years had a covariate-adjusted hazard ratio of 0.57 (95% CI, 0.41-0.81) compared with women with a BMI between 20.0 and 22.4 at age 18 years. This association did not appreciably change when adjusting for current BMI (Table 3). Similarly, adjustment for waist-hip ratio did not alter the association (data not shown).

Separate analyses were also performed for ER-positive and ER-negative breast cancer cases and for PR-positive and PR-negative breast cancer cases. The association between current BMI and premenopausal breast cancer incidence was stronger for ER-positive than ER-negative cases (P for heterogeneity = .19), whereas no apparent difference was observed between PR-positive and PR-negative cases (P for heterogeneity = .94) (Table 4). The association with BMI at age 18 years was also strongest for ER-positive breast cancer (P for heterogeneity = .68 for ER and 0.78 for PR) (Table 5). When we stratified by menstrual cycle length at ages 18 to 22 years (<32 vs ≥32 days), associations were somewhat stronger in women with longer cycle durations, but there was no significant heterogeneity (P for heterogeneity = .72) (Table 6). No effect modification by age or use of oral contraceptives was apparent.

Women with probable PCOS had a covariate-adjusted hazard ratio for breast cancer of 0.89 (95% CI, 0.71-1.10) compared with women who were unlikely to have PCOS. When also adjusting for BMI at age 18 years and for current BMI, the hazard ratio for breast cancer associated with PCOS was 0.98 (95% CI, 0.78-1.23), indicating that any association between PCOS and breast cancer is likely to be mediated by BMI rather than other characteristics of PCOS.

COMMENT

Among the premenopausal participants in the NHS II, a high BMI was inversely associated with the incidence of breast cancer. This association was not explained by menstrual cycle characteristics, self-reported infertility due to an ovulatory disorder, or probable PCOS. The BMI at age 18 years, however, explained part of the association between current BMI and breast cancer incidence.

In several studies, an inverse association has been reported between body size and premenopausal breast cancer. Of studies in which the relation between BMI at ages 16 to 25 years and the risk of breast cancer was explored, a significant inverse association with premenopausal breast cancer risk was found in some11,1820 but not all.1,14,2126 High current BMI has been linked to a reduced risk of breast cancer in premenopausal women or in women younger than 50 to 55 years in numerous studies,112,14,18,19 but this link was not confirmed in other studies.20,21,2438 In a pooled analysis13 of 7 prospective cohort studies including 337 819 women and 723 incident cases of invasive premenopausal breast cancer, a nonlinear inverse association between BMI and breast cancer was found; women with a BMI exceeding 31 had a relative risk of 0.54 (95% CI, 0.34-0.85) compared with women with a BMI of 21 or less. In 3 studies,22,39,40 a positive association between BMI and breast cancer diagnosed before menopause or before age 55 years was observed.

Key and Pike41 suggested that the mechanism underlying the inverse association between BMI and premenopausal breast cancer is anovulation in the heavier women, resulting in decreased estradiol and progesterone levels. We cannot exclude a possible role of anovulation because we cannot measure anovulation directly. However, because adjustment for menstrual cycle patterns, infertility due to ovulatory disorder, probable PCOS, and use of oral contraceptives did not even slightly attenuate the association with BMI, anovulation does not seem to be a primary explanation for the reduced risk in heavier women. Among women with no history of infertility due to an ovulatory disorder, the inverse association between BMI and premenopausal breast cancer incidence persisted, lending further support to the role of mechanisms other than anovulation. In the same population, women with infertility due to an ovulatory disorder had a lower incidence of premenopausal breast cancer,42 whereas menstrual cycle pattern was not associated with breast cancer incidence except in women younger than 40 years.43

In this population of premenopausal women, BMI during earlier periods of adult life was more consistently associated with breast cancer incidence than BMI during adulthood. Body fatness during childhood has also been related to a lower incidence of breast cancer in the premenopausal women of the NHS II.44 A high BMI during adulthood is highly correlated with a high body mass during adolescence, which may be more important for the development of breast cancer before menopause. Although a high birth weight has been fairly consistently linked to an increase in the risk of premenopausal breast cancer,45 the BMI–breast cancer association seems to reverse at some point during the first years of life, only to revert back after menopause.46

Because BMI was more clearly related to ER-positive than ER-negative breast cancer, a role of sex steroid hormones is likely. High plasma estradiol levels have been associated with an increased risk of premenopausal breast cancer in some studies4750 but not in others.5153 Most studies collected samples at any time in the menstrual cycle, making interpretation more difficult given the fluctuation of estradiol levels and other sex steroid hormone levels throughout the menstrual cycle. In the NHS II, 18 506 premenopausal women provided blood samples in the early follicular and midluteal phases; higher levels of follicular total and free estradiol levels were associated with an increased incidence of breast cancer, whereas no association was apparent for estradiol levels in the luteal phase.50

Premenopausal overweight women have been found to have lower estradiol levels than lean women, but the evidence is inconsistent.5474 In studies in which the collection of blood specimens was timed during the menstrual cycle,5465,71 a significant inverse association between total estradiol concentration and BMI was found in 45457 and a nonsignificant inverse association was found in another.65 In the NHS II, we also observed a significant inverse association between total estradiol level during the follicular and luteal phases and BMI at blood sampling but not between free estradiol level and BMI.75 Obese women have decreased levels of sex hormone–binding globulin.5457,6074 Because sex hormone–binding globulin is the main protein carrier of estradiol, free estradiol levels should increase with higher BMI, but the pituitary gland and hypothalamus regulate free estradiol in premenopausal women; hence ovarian production of estradiol may be kept low.76 Potischman et al55 suggested that more free estradiol may be cleared by the liver and other tissues in obese women. Alternatively, obese women may experience ovulatory insufficiency, resulting in compromised estradiol production capacity.75 Whether decreased estrogen blood levels in obese premenopausal women explain the inverse association with breast cancer remains to be determined. The observation that this inverse association is stronger for ER-positive breast cancer lends support to this mechanism.

Finally, detection bias has to be considered as a possible explanation for the observed associations. Obese women are less likely to seek breast cancer screening than normal-weight women.7779 It is possible that obese women with preclinical breast cancer delay their diagnosis, moving the detection of their cancer from the premenopausal to the postmenopausal phase.

In conclusion, a large body size during early adulthood is inversely related to the incidence of breast cancer in premenopausal women. Factors related to ovulation, such as menstrual cycle characteristics, infertility due to an ovulatory disorder, and probable PCOS, do not seem to explain this association.

Back to top
Article Information

Correspondence: Karin B. Michels, ScD, PhD, Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115.

Accepted for Publication: August 18, 2006.

Author Contributions:Study concept and design: Michels. Acquisition of data: Michels and Willett. Analysis and interpretation of data: Michels and Terry. Drafting of the manuscript: Michels. Critical revision of the manuscript for important intellectual content: Michels, Terry, and Willett. Statistical analysis: Michels and Terry. Obtained funding: Michels and Willett. Study supervision: Michels.

Financial Disclosure: None reported.

Funding/Support: This project was supported by a grant from the Massachusetts Breast Cancer Research Grants Program of the Massachusetts Department of Public Health (Dr Michels). The NHS II is supported by Public Health Service grant CA50385 from the National Cancer Institute, National Institutes of Health, US Department of Health and Human Services.

References
1.
Brinton  LASwanson  CA Height and weight at various ages and risk of breast cancer. Ann Epidemiol 1992;2597- 609
PubMedArticle
2.
Harris  RENamboodiri  KKWynder  EL Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992;841575- 1582
PubMedArticle
3.
Vatten  LJKvinnsland  S Prospective study of height, body mass index and risk of breast cancer. Acta Oncol 1992;31195- 200
PubMedArticle
4.
Bruning  PFBonfrer  JMHart  AA  et al.  Body measurements, estrogen availability and the risk of human breast cancer: a case-control study. Int J Cancer 1992;5114- 19
PubMedArticle
5.
Petrek  JAPeters  MCirrincione  CRhodes  DBajorunas  D Is body fat topography a risk factor for breast cancer? Ann Intern Med 1993;118356- 362
PubMedArticle
6.
Tornberg  SACarstensen  JM Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer 1994;69358- 361
PubMedArticle
7.
Taioli  EBarone  JWynder  EL A case-control study on breast cancer and body mass. Eur J Cancer 1995;31A723- 728
PubMedArticle
8.
Franceschi  SFavero  ALa Vecchia  C  et al.  Body size indices and breast cancer risk before and after menopause. Int J Cancer 1996;67181- 186
PubMedArticle
9.
Hu  YHNagata  CShimizu  HKaneda  NKashiki  Y Association of body mass index, physical activity, and reproductive histories with breast cancer: a case-control study in Gifu, Japan. Breast Cancer Res Treat 1997;4365- 72
PubMedArticle
10.
Tavani  AGallus  SLa Vecchia  C  et al.  Risk factors for breast cancer in women under 40 years. Eur J Cancer 1999;351361- 1367
PubMedArticle
11.
Peacock  SLWhite  EDaling  JRVoigt  LFMalone  KE Relation between obesity and breast cancer in young women. Am J Epidemiol 1999;149339- 346
PubMedArticle
12.
Hall  IJNewman  BMillikan  RCMoorman  PG Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 2000;151754- 764
PubMedArticle
13.
van den Brandt  PASpiegelman  DYaun  SS  et al.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152514- 527
PubMedArticle
14.
de Vasconcelos  ABAzevedo e Silva Mendonca  GSichieri  R Height, weight, weight change and risk of breast cancer in Rio de Janeiro, Brazil. Sao Paulo Med J 2001;11962- 66
PubMedArticle
15.
Friedenreich  CM Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001;1015- 32
PubMedArticle
16.
Cox  DR Regression models and life tables (with discussion). J R Stat Soc Ser B 1972;34187- 220
17.
Marshall  RJChisholm  EM Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med 1985;4337- 344
PubMedArticle
18.
Huang  ZHankinson  SEColditz  GA  et al.  Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;2781407- 1411
PubMedArticle
19.
Coates  RJUhler  RJHall  HI  et al.  Risk of breast cancer in young women in relation to body size and weight gain in adolescence and early adulthood. Br J Cancer 1999;81167- 174
PubMedArticle
20.
Folsom  ARKaye  SAPrineas  RJPotter  JDGapstur  SMWallace  RB Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 1990;131794- 803
PubMed
21.
Lund  EAdami  HOBergstrom  RMeirik  O Anthropometric measures and breast cancer in young women. Cancer Causes Control 1990;1169- 172
PubMedArticle
22.
Mayberry  RM Age-specific patterns of association between breast cancer and risk factors in black women, ages 20 to 39 and 40 to 54. Ann Epidemiol 1994;4205- 213
PubMedArticle
23.
Ursin  GPaganini-Hill  ASiemiatycki  JThompson  WDHaile  RW Early adult body weight, body mass index, and premenopausal bilateral breast cancer: data from a case-control study. Breast Cancer Res Treat 1995;3375- 82
PubMedArticle
24.
Hirose  KTajima  KHamajima  N  et al.  Association of family history and other risk factors with breast cancer risk among Japanese premenopausal and postmenopausal women. Cancer Causes Control 2001;12349- 358
PubMedArticle
25.
Shu  XOJin  FDai  Q  et al.  Association of body size and fat distribution with risk of breast cancer among Chinese women. Int J Cancer 2001;94449- 455
PubMedArticle
26.
Wenten  MGilliland  FDBaumgartner  KSamet  JM Associations of weight, weight change, and body mass with breast cancer risk in Hispanic and non-Hispanic white women. Ann Epidemiol 2002;12435- 444
PubMedArticle
27.
McNee  RKMason  BHNeave  LMKay  RG Influence of height, weight, and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat 1987;9145- 150
PubMedArticle
28.
Schatzkin  APalmer  JRRosenberg  L  et al.  Risk factors for breast cancer in black women. J Natl Cancer Inst 1987;78213- 217
PubMed
29.
Parazzini  Fla Vecchia  CNegri  EBruzzi  PPalli  DBoyle  P Anthropometric variables and risk of breast cancer. Int J Cancer 1990;45397- 402
PubMedArticle
30.
Mannisto  SPietinen  PPyy  MPalmgren  JEskelinen  MUusitupa  M Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status. Int J Cancer 1996;688- 13
PubMedArticle
31.
Chie  WCLi  CYHuang  CSChang  KJLin  RS Body size as a factor in different ages and breast cancer risk in Taiwan. Anticancer Res 1998;18565- 570
PubMed
32.
Galanis  DJKolonel  LNLee  JLe Marchand  L Anthropometric predictors of breast cancer incidence and survival in a multi-ethnic cohort of female residents of Hawaii, United States. Cancer Causes Control 1998;9217- 224
PubMedArticle
33.
Kaaks  RVan Noord  PADen Tonkelaar  IPeeters  PHRiboli  EGrobbee  DE Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch “DOM” cohort. Int J Cancer 1998;76647- 651
PubMedArticle
34.
Tung  HTTsukuma  HTanaka  H  et al.  Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn J Clin Oncol 1999;29137- 146
PubMedArticle
35.
Enger  SMRoss  RKPaganini-Hill  ACarpenter  CLBernstein  L Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev 2000;9681- 687
PubMed
36.
Adebamowo  CAOgundiran  TOAdenipekun  AA  et al.  Waist-hip ratio and breast cancer risk in urbanized Nigerian women. Breast Cancer Res 2003;5R18- R24
PubMedArticle
37.
Adebamowo  CAOgundiran  TOAdenipekun  AA  et al.  Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol 2003;13455- 461
PubMedArticle
38.
Lahmann  PHHoffmann  KAllen  N  et al.  Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2004;111762- 771
PubMedArticle
39.
Chu  SYLee  NCWingo  PASenie  RTGreenberg  RSPeterson  HB The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study. J Clin Epidemiol 1991;441197- 1206
PubMedArticle
40.
Chang  SBuzdar  AUHursting  SD Inflammatory breast cancer and body mass index. J Clin Oncol 1998;163731- 3735
PubMed
41.
Key  TJPike  MC The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;2429- 43
PubMedArticle
42.
Terry  KLWillett  WCRich-Edwards  JWMichels  KB A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med In press
43.
Terry  KLWillett  WCRich-Edwards  JWHunter  DJMichels  KB Menstrual cycle characteristics and incidence of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2005;141509- 1513
PubMedArticle
44.
Baer  HJColditz  GARosner  BA  et al.  Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women. Breast Cancer Res 2005;7R314- R325
PubMedArticle
45.
Michels  KBXue  F Role of birthweight in the etiology of breast cancer. Int J Cancer 2006;1192007- 2025
PubMedArticle
46.
Michels  KBWillett  WC Breast cancer: early life matters. N Engl J Med 2004;3511679- 1681
PubMedArticle
47.
Rosenberg  CRPasternack  BSShore  REKoenig  KLToniolo  PG Premenopausal estradiol levels and risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 1994;140518- 525
PubMed
48.
Thomas  HVKey  TJAllen  DS  et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. Br J Cancer 1997;751075- 1079
PubMedArticle
49.
Kabuto  MAkiba  SStevens  RGNeriishi  KLand  CE A prospective study of estradiol and breast cancer among Japanese women. Cancer Epidemiol Biomarkers Prev 2000;9575- 579
PubMed
50.
Eliassen  AHMissmer  SATworoger  SS  et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;981406- 1415Article
51.
Wysowski  DKComstock  GWHelsing  KJLau  HL Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125791- 799
PubMed
52.
Helzlsouer  KJAlberg  AJBush  TLLongcope  CGordon  GBComstock  GW A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;1879- 85
PubMed
53.
Kaaks  RBerrino  FKey  T  et al.  Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97755- 765
PubMedArticle
54.
Grenman  SRonnemaa  TIrjala  KKaihola  HLGronroos  M Sex steroid, gonadotropin, cortisol, and prolactin levels in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight reduction. J Clin Endocrinol Metab 1986;631257- 1261
PubMedArticle
55.
Potischman  NSwanson  CASiiteri  PHoover  RN Reversal of relation between body mass and endogenous concentrations with menopausal status. J Natl Cancer Inst 1996;88756- 758
PubMedArticle
56.
Randolph  JFSowers  MGold  EB  et al.  Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003;881516- 1522
PubMedArticle
57.
Verkasalo  PKThomas  HVAppleby  PNDavey  GKKey  TJ Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women. Cancer Causes Control 2001;1247- 59
PubMedArticle
58.
Zumoff  B Relationship of obesity to blood estrogens. Cancer Res 1982;42 ((8 suppl)) 3289s- 3294s
PubMed
59.
Trichopoulos  DPolychronopoulou  ABrown  JMacMahon  B Obesity, serum cholesterol, and estrogens in premenopausal women. Oncology 1983;40227- 231
PubMedArticle
60.
Haffner  SMKatz  MSStern  MPDunn  JF Relationship of sex hormone binding globulin to overall adiposity and body fat distribution in a biethnic population. Int J Obes 1989;131- 9
PubMed
61.
Dorgan  JFReichman  MEJudd  JT  et al.  The relation of body size to plasma levels of estrogens and androgens in premenopausal women (Maryland, United States). Cancer Causes Control 1995;63- 8
PubMedArticle
62.
De Pergola  GZamboni  MSciaraffia  M  et al.  Body fat accumulation is possibly responsible for lower dehydroepiandrosterone circulating levels in premenopausal obese women. Int J Obes Relat Metab Disord 1996;201105- 1110
PubMed
63.
Westhoff  CGentile  GLee  JZacur  HHelbig  D Predictors of ovarian steroid secretion in reproductive-age women. Am J Epidemiol 1996;144381- 388
PubMedArticle
64.
Nagata  CKaneda  NKabuto  MShimizu  H Factors associated with serum levels of estradiol and sex hormone-binding globulin among premenopausal Japanese women. Environ Health Perspect 1997;105994- 997
PubMedArticle
65.
Thomas  HVKey  TJAllen  DS  et al.  Re: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status [letter]. J Natl Cancer Inst 1997;89396- 397
PubMedArticle
66.
Ivandic  APrpic-Krizevac  ISucic  MJuric  M Hyperinsulinemia and sex hormones in healthy premenopausal women: relative contribution of obesity, obesity type, and duration of obesity. Metabolism 1998;4713- 19
PubMedArticle
67.
Kraemer  RRSynovitz  LBGimpel  TKraemer  GRJohnson  LGCastracane  VD Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. Metabolism 2001;50488- 493
PubMedArticle
68.
Allen  NEAppleby  PNKaaks  RRinaldi  SDavey  GKKey  TJ Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women. Cancer Causes Control 2003;1465- 74
PubMedArticle
69.
Kok  PRoelfsema  FFrolich  MMeinders  AEPijl  H Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004;894445- 4449
PubMedArticle
70.
Tufano  AMarzo  PEnrini  RMorricone  LCaviezel  FAmbrosi  B Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause. J Endocrinol Invest 2004;27648- 653
PubMedArticle
71.
Lukanova  ALundin  EZeleniuch-Jacquotte  A  et al.  Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004;150161- 171
PubMedArticle
72.
Bezemer  IDRinaldi  SDossus  L  et al.  C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005;16561- 572
PubMedArticle
73.
Kopelman  PGPilkington  TRWhite  NJeffcoate  SL Abnormal sex steroid secretion and binding in massively obese women. Clin Endocrinol (Oxf) 1980;12363- 369
PubMedArticle
74.
Pasquali  RAntenucci  DMelchionda  N  et al.  Sex hormones in obese premenopausal women and their relationships to body fat mass and distribution, B cell function and diet composition. J Endocrinol Invest 1987;10345- 350
PubMedArticle
75.
Tworoger  SSEliassen  AHMissmer  SA  et al.  Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women. Cancer Epidemiol Biomarker Prev In press
76.
Yen  SJaffe  RBarbieri  R Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management.  Philadelphia, Pa WB Saunders Co1999;
77.
Wee  CCMcCarthy  EPDavis  RBPhillips  RS Screening for cervical and breast cancer: is obesity an unrecognized barrier to preventive care? Ann Intern Med 2000;132697- 704
PubMedArticle
78.
Wee  CCMcCarthy  EPDavis  RBPhillips  RS Obesity and breast cancer screening. J Gen Intern Med 2004;19324- 331
PubMedArticle
79.
Amy  NKAalborg  ALyons  PKeranen  L Barriers to routine gynecological cancer screening for white and African-American obese women. Int J Obes 2006;30147- 155Article
×